Comparative antihypertensive effectiveness of once-daily mibefradil and diltiazem CD

Clinical Therapeutics

Volumn 19, Issue 5, 1997, Pages 954-962

  Bittar, Neville ^a  

^a University of Wisconsin Health   (United States)

Author keywords

Calcium antagonist; Diltiazem CD; Drug therapy of hypertension; Mibefradil

Indexed keywords

DILTIAZEM DERIVATIVE; MIBEFRADIL;

ANTIHYPERTENSIVE THERAPY; ARTICLE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FATIGUE; FEMALE; HEADACHE; HUMAN; HYPERTENSION; LEG EDEMA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MUSCLE WEAKNESS; RANDOMIZED CONTROLLED TRIAL; RASH; VERTIGO;

EID: 0030697365     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/S0149-2918(97)80048-3     Document Type: Article

References (18)

1. 2+ channel blocker with potent vasodilator but weak inotropic action. J Cardiovasc Pharmacol. 1989;13:754-759.
2. 2+ channels by Ro 40-5967. Circ Res. 1994;75:144-148.
3. 2+ channel in cardiac tissue. Eur J Pharmacol. 1995;290:155-158.
4. Schmitt R, Kleinbloesem C, Belz G, et al. Hemodynamic and humoral effects of the novel calcium antagonist Ro 40-5967 in patients with hypertension. Clin Pharmacol Ther. 1992;52:314-323.
5. Rousseau M, Hayashida W, van Eyll C, et al. Hemodynamic and cardiac effects of the selective T-type and L-type calcium channel blocker, mibefradil, in patients with varying degrees of left ventricular systolic dysfunction. J Am Coll Cardiol. 1996;28:972-979.
6. Ezzaher A, Bouanani N, Su J, et al. Increased negative inotropic effect of calcium channel blockers in hypertrophied and failing rabbit heart. J Pharmacol Exp Ther. 1991;257:466-471.
7. 3H] desmethoxyverapamil receptor, is devoid of the negative inotropic effects of verapamil in normal and failing rat hearts. Cardiovasc Drugs Ther. 1990;4:731-736.
8. Welker H, Eggers H, Kleinbloesem C, et al. Ro 40-5967: Pharmacokinetics of a new calcium antagonist. Eur J Clin Pharmacol. 1989;36:A304. Abstract.
9. Bernink P, Prager G, Schelling A, Kobrin I. Antihypertensive properties of the novel calcium antagonist mibefradil (Ro 40-5967): A new generation of calcium antagonists? Hypertension. 1996;27:426-432.
10. Oparil S, Kobrin I, Abernethy D, et al. Dose-response characteristics of mibefradil, a novel calcium antagonist, in the treatment of essential hypertension. Am J Hypertens. 1997;10:735-742.
11. Carney S, Wing L, Ribeiro A, et al. The addition of mibefradil to chronic hydrochlorothiazide therapy in hypertensive patients is associated with a significant antihypertensive effect. J Hum Hypertens. 1997;11:387-393.
12. Bakx A, van der Wall E, Braun S, et al. Effects of the new calcium antagonist mibefradil (Ro 40-5967) on exercise duration in patients with chronic stable angina pectoris: A multicenter, placebo-controlled study. Am Heart J. 1995;130:748-757.
13. Alpert J, Kobrin I, DeQuattro V, et al. Additional anti-anginal and anti-ischemic efficacy of mibefradil in patients pretreated with a beta-blocker for chronic stable angina pectoris. Am J Cardiol. 1997;79: 1025-1030.
14. Bursztyn M, Kadr H, Tilvis R, et al. Mibefradil, a novel calcium antagonist, in elderly hypertensives: Favorable hemodynamics and pharmacokinetics. Am Heart J. 1997;134:238-247.
15. Massie B, Chrysant S, Jain A, et al. Anti-hypertensive effects of mibefradil: A double-blind comparison with diltiazem CD. Clin Cardiol. 1997;20:562-568.
16. Clozel J-P, Banken L, Osterrieder W. Effects of Ro 40-5967, a novel calcium antagonist, on myocardial function during ischemia induced by lowering coronary perfusion pressure in dogs: Comparison with verapamil. J Cardiovasc Pharmacol. 1989;14:713-721.
17. Véniant M, Clozel J-P, Hess P, Wolfgang R. Ro 40-5967, in contrast to diltiazem, does not reduce left ventricular contractility in rats with chronic myocardial infarction. J Cardiovasc Pharmacol. 1991:17: 277-284.
18. Levine T. The design of the Mortality Assessment in Congestive Heart Failure trial (MACH-1, mibefradil). Clin Cardiol. 1997;20:320-326.